Top Banner
Chapter 5 Therapy for Fungi and Viruses BY : SANJAY RAJPUROHIT
90
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Chapter05

Chapter 5

Therapy for Fungi and Viruses

BY : SANJAY RAJPUROHIT

Page 2: Chapter05

Chapter 5 Topics

• Fungi and Antifungals

• Viruses and Antivirals

• Antiretrovirals

Page 3: Chapter05

Learning Objectives

• Understand the differences between fungi and viruses and why the drugs to treat them must have very different mechanisms of action.

• Differentiate antifungals, antivirals, and antiretrovirals by their indications, therapeutic effects, side effects, dosages, and administration.

• Use antifungal, antiviral, and antiretroviral terminology correctly in written and oral communication.

• Define differences in mechanisms of action of antibiotics, antifungals, antivirals, and antiretrovirals.

Page 4: Chapter05

Fungi and Their Characteristics

Fungus – Single-cell

organism– Lack of chlorophyll– Rigid cell wall and

nucleus– Reproduction by

spores

Page 5: Chapter05

Discussion

In what ways are fungal cells similar to human cells? How are they different?

Page 6: Chapter05

Discussion

In what ways are fungal cells similar to human cells? How are they different?

Answer: Human cell membranes contain cholesterol, and cell membranes of fungi contain ergosterol.

Page 7: Chapter05

Fungi and Their Characteristics

Organism Disease

Aspergillus Aspergillosis

Blastomyces Blastomycosis

Candida (yeast) Candidiasis

Coccidioides Coccidioidomycosis

Cryptococcus Cryptococcosis

Histoplasma Histoplasmosis

Page 8: Chapter05

Antifungals

How They Work– Prevent synthesis of ergosterol– Because human cells use cholesterol,

human cells are affected minimally

Page 9: Chapter05

Antifungals

Dispensed in Two Forms– Topical Agents– Systemic Agents

Page 10: Chapter05

Antifungals

• amphotericin B (Abelcet, AmBisome, Amphocin, Amphotec, Fungizone)

• butenafine (Mentax)• caspofungin (Cancidas)• ciclopirox (Loprox, Penlac)• clotrimazole (Gyne-Lotrimin, Mycelex-7)• clotrimazole-betamethasone (Lotrisone)• fluconazole (Diflucan)• flucytosine (Ancobon)• griseofulvin (Fulvicin P/G, Gris-PEG)

Drug List

Page 11: Chapter05

Antifungals

• itraconazole (Sporanox)• ketoconazole (Nizoral)• miconazole (Lotrimin AF, Monistat Derm, Monistat 3)• nystatin (Mycostatin)• sertaconazole (Ertaczo)• terbinafine (Lamisil)• terconazole (Terazol)• voriconazole (VFEND)

Drug List

Page 12: Chapter05

Antifungal Side Effects

• Serious side effects have been reported, even for topical agents.

• Pay close attention to dosing regimen to avoid overdosing.

Page 13: Chapter05

amphotericin B (Fungizone)

• Used for blood-born, life-threatening fungal infections

• Infused slowly, not piggybacked, and not mixed with normal saline

• Blood levels of drug monitored and vitals monitored during infusion

• During treatment, monitor electrolytes, BUN, serum creatinine, temperature, CBC, fluid input and output

• Side effects: renal toxicity, anemia, fever, chills, shaking, headache

Page 14: Chapter05

voriconazole (VFEND)

• Alternative to amphotericin B

• Can be started IV and switched to oral

• Can cause liver toxicity and blurred vision

Page 15: Chapter05

fluconazole (Diflucan)

• Oral form used for vaginal or oral candidiasis

• IV used for patients who cannot tolerate oral

• Commonly prescribed medication

• Side effects: headache, rash, GI upset

Page 16: Chapter05

itraconazole (Sporanox)

• Fungal infections of nails• Capsule taken twice a day with a fatty meal

and taken with a cola to increase stomach acidity and increase absorption

• Not in conjunction with antacids or H2 blockers

• Can cause liver toxicity• Capsules not substituted for oral solution due

to absorption issues

Page 17: Chapter05

terbinafine (Lamisil)

• Kills fungus instead of just inhibiting growth• Oral form taken once daily

– Six weeks for fingernails – Twelve weeks for toenails

• Pulse dosing works well• Topical form for athlete’s foot, jock itch, and

ringworm– Do not use vaginally– Do not exceed four weeks

Page 18: Chapter05

Antifungal Dispensing Issues

Lamisil, Lomotil, and Lamictal look alike.Use dose and dosage form to help keep these drugs from being dispensed incorrectly.

Warning!

Page 19: Chapter05

grisefulvin (Fulvicin P/G, Gris-PEG)

• Fungal infections of the hair, skin, and nails

• Take with a fatty meal

• Avoid exposure to sunlight

• Dizziness and drowsiness are side effects, as well as passing headache

Page 20: Chapter05

clotrimazole(Gyne-Lotrimin, Mycelex-7)

• Effective against oral candidiasis

• Supplied as a troche

• Available as OTC vaginal cream

• Topical form is the DOC for ringworm

Page 21: Chapter05

clotrimazole-betamethasone (Lotrisone)

• Cream and lotion

• Commonly prescribed medication

Page 22: Chapter05

miconazole(Lotrimin AF, Monistat Derm,

Monistat 3)

• Treatment of vulvovaginal candidiasis

• Available OTC

Page 23: Chapter05

nystatin(Mycostatin)

• For patients with oral candidiasis

• Often used in liquid form, swish and swallow

Page 24: Chapter05

ciclopirox (Loprox, Penlac)

• “Nail polish” treats nail tissue infections

• Do not take in combination with other oral antifungals

• Dispensed in amber-colored container

• Apply at bedtime to avoid exposure to light

Page 25: Chapter05

Viruses and Their Characteristics

Virus – Does not have

components of a cell

– Unable to replicate outside of a living host cell

A virus infecting a bacterium.

Page 26: Chapter05

Viruses and Their Characteristics

Most viruses are spread through the following routes:

– Direct contact– Ingestion of contaminated food and water– Inhalation of airborne particles– Exposure to contaminated body

fluids/equipment

Page 27: Chapter05

Viruses and Their Characteristics

• Parts of a virus particle, virion– Nucleic acid consisting of either DNA or

RNA, not both– Capsid (protein shell) that surrounds and

protects the nucleic acid

• Naked virus– Virus without an envelope covering the

capsid

Page 28: Chapter05

Stages of Viral Infection

1. Virus attaches to a cell receptor.

Page 29: Chapter05

Stages of Viral Infection

1. Virus attaches to a cell receptor.

2. Cell membrane indents and closes around the virus, thus the virus penetrates the cell.

Page 30: Chapter05

Stages of Viral Infection

1. Virus attaches to a cell receptor.

2. Cell membrane indents and closes around the virus, thus the virus penetrates the cell.

3. Virus escapes into cytoplasm.

Page 31: Chapter05

Stages of Viral Infection

1. Virus attaches to a cell receptor.2. Cell membrane indents and closes

around the virus, thus the virus penetrates the cell.

3. Virus escapes into cytoplasm.4. Virus uncoats, shedding its

covering and releasing DNA or RNA into cell nucleus.

Page 32: Chapter05

Stages of Viral Infection

1. Virus attaches to a cell receptor.2. Cell membrane indents and closes around

the virus, thus the virus penetrates the cell.3. Virus escapes into cytoplasm.4. Virus uncoats, shedding its covering and

releasing DNA or RNA into cell nucleus.5. Virus thus converts nuclear activity in

the cell to viral activity and reproduces new viral particles.

Page 33: Chapter05

Discussion

Provide an example of a common viral infection and the symptoms of this condition.

Page 34: Chapter05

Discussion

Provide an example of a common viral infection and the symptoms of this condition.

Answer: The flu (influenza). Symptoms include malaise, myalgia (muscle pain), headache, chills, fever.

Page 35: Chapter05

Viral Classification

Two ways that viral infections are classified

– Duration and severity– Infection

Page 36: Chapter05

Viral Classification

• Duration and severity– Acute: quickly resolves with no latent

infection such as common cold and flu– Chronic: protracted course with long

periods of remission interspersed with reappearance such as herpes virus infection

– Slow: progressive course, ultimately ending in death

Page 37: Chapter05

Viral Classification

• Infection– Local: affects tissues of a single system,

such as the respiratory tract, the eye, or the skin

– Generalized: has spread or is spreading to other tissues by way of bloodstream or tissues of the CNS

Page 38: Chapter05

Virus and Cell Interaction

A virus can damage a host cell in the following ways:

– Kill the host cell– Alter the cell– Incorporate into the genetic material of the

host cell– Divide when the host cell divides

Page 39: Chapter05

Virus and Cell Interaction

Immunoglobulinantibody that may prevent an organism from attaching to a cell receptor and may destroy the organism

Page 40: Chapter05

Virus and Cell Interaction

Interferona substance that exerts virus-nonspecific but host-specific antiviral activity by inducing gene coding for antiviral proteins that inhibit the synthesis of viral RNA

Page 41: Chapter05

Virus and Cell Interaction

Vaccination– Exposes the patient to a component of a

virus or a similar strain that does not produce infection.

– When a vaccinated patient encounters the actual virus, the infection cannot develop.

Page 42: Chapter05

Discussion

Who should receive an influenza vaccine?

Page 43: Chapter05

Discussion

Who should receive an influenza vaccine?

Answer: High-risk patients such as healthcare workers, nursing home residents, public safety workers, individuals over 65 years old, immunocompromised patients.

Page 44: Chapter05

Antivirals

Prevent virus cell replication without interfering with host cell’s normal function.

Page 45: Chapter05

Antivirals

Systemic Agents• acyclovir (Zovirax)• amantadine (Symmetrel)• cidofovir (Vistide)• famciclovir (Famvir)• foscarnet (Foscavir)• ganciclovir (Cytovene)

Drug List

Page 46: Chapter05

Antivirals

Systemic Agents• oseltamivir (Tamiflu)• ribavirin (Copegus, Rebetol, Virazole)• rimantadine (Flumadine)• valacyclovir (Valtrex)• valganciclovir (Valcyte)• zanamivir (Relenza)

Drug List

Page 47: Chapter05

Antivirals

Ocular Agent

• ganciclovir (Vitrasert)

Drug List

Page 48: Chapter05

Therapeutic Uses of Antivirals

• Cytomegalovirus (CMV) retinitis

• Herpes simplex

• Herpes simplex keratitis

• Herpes zoster (shingles)

• Influenza prophylaxis

• Varicella (chicken pox)

Page 49: Chapter05

Antiviral Side Effects

Range from mild to severe.– Mild: headache– Severe: renal disorders

Page 50: Chapter05

Antiviral Dispensing Issues

Amatadine, rimantadine, and ranitidine can be easily confused.

Dosing and indications will help keep them straight.

Warning!

Page 51: Chapter05

acyclovir (Zovirax)

• Treatment of– Genital herpes– Herpes zoster (shingles)– Varicella (chicken pox) – Herpes encephalitis (in IV form)

• Range of short- and long-term side effects reported

Page 52: Chapter05

famciclovir (Famvir)

• Treatment of – Acute herpes zoster– Herpes simplex in immunocompromised

patients– Genital herpes

• Dosed less frequently than acyclovir

• Prodrug

Page 53: Chapter05

valacyclovir (Valtrex)

• Treats herpes zoster in immunocompetent adults and genital herpes

• Take with water and within forty-eight hours of the onset of zoster rash

• Shortens duration of postherpetic neuralgia• Commonly prescribed medication• Side effects: nausea, vomiting, diarrhea,

constipation

Page 54: Chapter05

zanamivir (Relenza)

• Treatment of influenza A and B• Therapy initiated within 48 hr of symptom

onset• 2 inhalations daily, at 12 hr intervals, for 5

days• If using brochodilator, use it immediately

prior to admin of zanamivir• Sometimes Rx as prophylactic

Page 55: Chapter05

oseltamivir (Tamiflu)

• Prevents influenza A and B

• Initiated within forty-eight hours of symptom onset

• Food improves tolerance

Page 56: Chapter05

ganciclovir (Cytovene)

• Treating cytomegalovirus (CMV) infections in immunocompromised patients

• Follow chemotherapy preparations and dispensing guidelines when mixing, labeling, and packaging

• IV form not used for rapid or bolus injection

Page 57: Chapter05

Antiviral Dispensing Issues

• Cytovene and Cytosar might be confused. – Cytovene: 250 mg, 500 mg– Cytosar: Chemotherapy agent, 10 mg

Warning!

Page 58: Chapter05

foscarnet (Foscavir)

• Treatment of CMV infections in immunocompromised patients

• IV infusion, not rapid or bolus injection

• Patient must be hydrated, and Rx for hydration should be included with order for drug

Page 59: Chapter05

Antiviral Dispensing Issues

• Patients who are given ganciclovir (Cytovene) or foscarnet (Foscavir) IV must be well hydrated.

• Typically there are “standing orders” for hydration when these drugs are prescribed.

Warning!

Page 60: Chapter05

ribavirin (Virazole)

• Treating viral infections and pediatric patients with RSV

• Absorbed systemically from the respiratory tract following nasal and oral inhalation

• Side effects: fatigue, headache, insomnia, nausea, anorexia

Page 61: Chapter05

Antiretrovirals

• Developed to limit the progression of the retrovirus HIV, the cause of AIDS

Page 62: Chapter05

Antiretrovirals

• Developed to limit the progression of the retrovirus HIV, the cause of AIDS

• Five classes of antiretroviral drugs

Page 63: Chapter05

Antiretrovirals

• Developed to limit the progression of the retrovirus HIV, the cause of AIDS

• Five classes of antiretroviral drugs– NRTIs– NNRTIs– NtRTIs– PIs– Fusion inhibitors

Page 64: Chapter05

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

• Inhibit the action of reverse transcriptase to prevent the formation of viral RNA from proviral DNA

• Cause a decrease in the amount of virus in the body and subsequent spread to other healthy cells

Page 65: Chapter05

NRTI Side Effects

• Lactic acidosis

• Degeneration of the liver

Page 66: Chapter05

NRTI Dispensing Issues

• Taken with or without food

• Generally do not interfere with other drugs

• Administered in two or three doses per day

Page 67: Chapter05

NRTIs

• abacavir (Ziagen)• didanosine (Videx)• emtricitabine (Emtriva)• lamivudine (Epivir)• stavudine (Zerit)• zalcitabine (Hivid)• zidovudine, AZT (Retrovir)• zidovudine-lamivudine (Combivir)• zidovudine-lamivudine-abacavir (Trizivir)

Drug List

Page 68: Chapter05

zidovudine (Retrovir)

• Previously called AZT• One of first drugs developed specifically for

treatment of HIV• Can be combined with all NRTIs except

stavudine • Used in combination with lamivudine (with

or without PI) used for needlestick or sexual exposure treatment

Page 69: Chapter05

lamivudine (Epivir)

• Treatment– HIV– Chronic hepatitis B

• Must be taken exactly as prescribed

• Fewest side effects of any of the NRTIs

Page 70: Chapter05

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

• Inhibit the action of HIV reverse transcriptase but at a different site on the enzyme than the site targeted by NRTIs

• Block RNA-dependent DNA polymerase activities

Page 71: Chapter05

NNRTIs

• delavirdine (Rescriptor)

• efavirenz (Sustiva)

• nevirapine (Viramune)

Drug List

Page 72: Chapter05

efavirenz (Sustiva)

• Dosed once a day, preferably at bedtime

• Patients should avoid high-fat meals• Side effects

– Dizziness, headache– Vivid dreams, nightmares, hallucinations– Typically occur 1-3 hr after administration– Typically subside after 2-4 weeks on drug

Page 73: Chapter05

nevirapine (Viramune)

• Lower dose first 2 weeks and then increased to appropriate therapeutic level to avoid rash

• The antibiotic rifampin interferes with this drug

• This drug decreases serum concentration of PIs

• Must monitor liver functions

Page 74: Chapter05

Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)

• Inhibit the activity of HIV-1 reverse transcriptase by competing with natural nucleic acid substrates

• Cause termination of chain formation after incorporating in viral nucleic acid

Page 75: Chapter05

NtRTIs

• tenofovir (Viread)

Drug List

Page 76: Chapter05

Protease Inhibitors (PIs)

• Inhibit the protease enzyme, which typically cleaves certain HIV protein precursors that are necessary for the replication of new infectious virons

• Results in production of immature, noninfectious virons

• Combined with other antiretroviral drugs

Page 77: Chapter05

PI Side Effects

• Protease paunch

• Facial atrophy

• Breast enlargement

• Hyperglycemia

• Hyperlipidemia

• Increase in bleeding episodes in hemophiliacs

Page 78: Chapter05

PIs

• amprenavir (Agenerase)• atazanavir (Reyataz)• fosamprenavir (Lexiva)• indinavir (Crixivan)• lopinavir-ritonavir (Kaletra)• nelfinavir (Viracept)• ritonavir (Norvir)• saquinavir (Fortovase, Invirase)

Drug List

Page 79: Chapter05

indinavir (Crixivan)

• Do not take with– St. John’s wort– Grapefruit juice– With food, especially high-fat

• Do take with a lot of water (48 oz/day) to avoid kidney stones

• Package with a desiccant, and patient to store in original container

Page 80: Chapter05

lopinavir-ritonavir (Kaletra)

• Combination inhibits metabolism of lopinavir, allowing increased plasma levels of lopinavir

• Side effects– Nausea and vomiting– Diarrhea– Pancreatitis

• Solution contains alcohol

Page 81: Chapter05

nelfinavir (Viracept)

• Can cause diarrhea, but loperamide and calcium carbonate can help control

• Take with food

Page 82: Chapter05

ritonavir (Norvir)

• Causes increase in serum concentrations and thus decreases dosage frequency of other PIs, thus decreasing side effects

• Given at a low dose• Take with food• Causes an altered sense of taste• Store in the refrigerator

Page 83: Chapter05

Fusion Inhibitors

How do fusion inhibitors represent an advance in the treatment of HIV?

Page 84: Chapter05

Fusion Inhibitors

How do fusion inhibitors represent an advance in the treatment of HIV?

Answer: Prevents AIDS virus from entering the immune cells.

Page 85: Chapter05

Fusion Inhibitors

• enfuvirtide (Fuzeon)

Drug List

Page 86: Chapter05

Responding to HIV Exposure

• Centers for Disease Control guidelines

• Post-exposure prophylaxis (PEP)

• Begin within two hours

• Can decrease risk of infection by 80%

Page 87: Chapter05

Combining AntiretroviralsRegimen Type Recommendation

standard therapy NNRTI: efavirenz + lamivudine + (zidovudine or tenofovir or stavudine)

PI: lopinavir-ritonavir + lamivudine + (zidovudine or stavudine)

alternative therapy 3 × NRTI: abacavir + lamivudine + (zidovudine or stavudine)

post-exposure prophylaxis (PEP)

zidovudine + lamivudine + (indinavir or nelfinavir)

Page 88: Chapter05

Antiretroviral Dispensing Issues

Avoid the following antiretroviral drug combinations:– didanosine with zalcitabine

– zidovudine with stavudine

– lamivudine with zalcitabine

– stavudine with zalcitabine

Warning!

Page 89: Chapter05

Discussion

What is one of the biggest problems when treating HIV?

Page 90: Chapter05

Discussion

What is one of the biggest problems when treating HIV?

Answer: Noncompliance with drug regimen due to problematic side effects and complex dosing.